Navigation Links
Depression and Autism Reviewed by NeuroPerspective
Date:3/8/2016

SAN DIEGO, March 8, 2016 /PRNewswire/ -- NI Research has released the March-April issue of NeuroPerspective, featuring comprehensive reviews of Depression and of Autism.

Logo - http://photos.prnewswire.com/prnh/20160307/341407LOGO

"Perhaps surprisingly, this may be one of the most optimistic issues NIR has ever produced, despite the angst that has swept the world's financial markets, roiled by intransigent conflicts, terrorist turbulence, and BizarroWorld politics; and where Biotech, a high-beta weathervane for winds from any direction, has seen valuations plummet," said NeuroPerspective publisher Harry Tracy, PhD.

The reason is twofold:

"Depression is the therapeutic area where the prospects for meaningful transformations in the current Treatment Paradigm are most accessible and probable. We are in or approaching Phase III with multiple strategies for providing rapid relief of depression, in a context where 'wait a few weeks' has been the perennial post-script to every new prescription. By 2020, the treatment landscape for depression will be transformed, undoing the death grip that the generics have had on the prospects for drug development for Psychiatry. On a longer-term track, Autism is the example of a paradigm shift underway, not yet in terms of treatment, but in research methodology. The use of real-time biosensors, in concert with large-population genomics and biomarkers, puts Autism on the leading edge for the emergence of a research paradigm with both conceptual and predictive validity," he said.

The Depression review includes assessments of programs from Janssen/JNJ, Allergan (from Naurex), Alkermes, Cerecor, and many others. Sidebars include assessments of the landscape in Post-Partum Depression, Suicidality, Bipolar Depression, and the ALKS 5461 pivotal program. The Autism review includes programs from Allergan/Rugen, Neuren, Roche, Simons Foundation, and numerous academic research institutions.

The March/April issue also provides company reviews for NeuroRx and Annexon Biosciences; commentary on the increased complexity now associated with the mHtt target in Huntington's; the Complement C4a system in schizophrenia; and a consideration of the Pharma industry's PR problems-'Why Do They Hate Us?'

About NI Research
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.

 A one-year (1-5 user) subscription to NeuroPerspective is $2525. Startup/academic pricing is available. The Depression/Autism review issue of NeuroPerspective is being offered as a single-issue purchase for $500.

NI Research also publishes NeuroLicensing, which comprehensively reviews current licensing trends in the CNS area, and assesses large and midsize pharma companies in terms of their licensing agendas and performance. In addition, NI Research provides consulting services to the pharma industry.

Further information and online purchasing with immediate download are available at http://www.niresearch.com/onlinestore.html.

Contact: NI Research, P.O. Box 1028, Cardiff CA 92007; 760-753-6376.
E-mail: info@niresearch.com

 

Contact:

Harry Tracy
NI Research
760-753-6376
Email 


'/>"/>
SOURCE NI Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System
2. NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression
3. Depression Study Published on BCM-95 Curcumin
4. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
5. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
6. New MTHFR Gene Test Extends Holistic Pharmacogenomics Approach to Treating Depression
7. The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
8. Studies Show Respiratory Motion Patient Monitor May be Early Warning System for Respiratory Depression
9. Northeasterners Are Tougher Than Other Regions, According to Winter Depression Symptom Research from InCrowd
10. Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression
11. Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):